Against a backdrop of declining sales for its branded hepatitis drugs, Gilead announced plans to launch its own “authorized generics” of two of its hep C treatments.
Simplifying Global Compliance
Gilead to Launch Generics for Its Hepatitis C Drugs
International Pharmaceutical Regulatory Monitor
